MX2019010994A - Metodos para tratar enfermedades y trastornos mediados por el complemento. - Google Patents
Metodos para tratar enfermedades y trastornos mediados por el complemento.Info
- Publication number
- MX2019010994A MX2019010994A MX2019010994A MX2019010994A MX2019010994A MX 2019010994 A MX2019010994 A MX 2019010994A MX 2019010994 A MX2019010994 A MX 2019010994A MX 2019010994 A MX2019010994 A MX 2019010994A MX 2019010994 A MX2019010994 A MX 2019010994A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- complement
- antibody
- individual
- treat diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471190P | 2017-03-14 | 2017-03-14 | |
| US201762553059P | 2017-08-31 | 2017-08-31 | |
| PCT/US2018/022462 WO2018170145A1 (en) | 2017-03-14 | 2018-03-14 | Methods for treating complement-mediated diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019010994A true MX2019010994A (es) | 2020-12-01 |
Family
ID=61873979
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010994A MX2019010994A (es) | 2017-03-14 | 2018-03-14 | Metodos para tratar enfermedades y trastornos mediados por el complemento. |
| MX2025010483A MX2025010483A (es) | 2017-03-14 | 2019-09-13 | Uso de anticuerpos y composiciones que los comprenden para tratar enfermedades y trastornos mediados por complemento |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025010483A MX2025010483A (es) | 2017-03-14 | 2019-09-13 | Uso de anticuerpos y composiciones que los comprenden para tratar enfermedades y trastornos mediados por complemento |
Country Status (14)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| ES2912396T3 (es) | 2012-11-02 | 2022-05-25 | Bioverativ Usa Inc | Anticuerpos anti-C1s del complemento y uso de los mismos |
| EP4212175A1 (en) | 2015-04-06 | 2023-07-19 | Bioverativ USA Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| IL326479A (en) | 2016-10-12 | 2026-04-01 | Bioverativ Usa Inc | Anti-c1s antibodies and methods of use thereof |
| PL3893924T3 (pl) | 2018-12-13 | 2025-01-13 | argenx BV | Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| JP2023503611A (ja) * | 2019-11-26 | 2023-01-31 | オメロス コーポレーション | 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法 |
| FI129383B (en) | 2020-06-15 | 2022-01-31 | Faron Pharmaceuticals Oy | Stable anti-clever-1 antibody formulation |
| BR112023001942A2 (pt) * | 2020-08-06 | 2023-02-28 | Bioverativ Usa Inc | Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento |
| TW202304508A (zh) | 2021-03-31 | 2023-02-01 | 美商百歐維拉提夫美國公司 | 減少冷凝集素疾病患者之手術相關溶血 |
| US12252550B2 (en) | 2021-05-20 | 2025-03-18 | Dianthus Therapeutics Opco, Inc. | Antibodies that bind to C1S and uses thereof |
| CN117642431B (zh) | 2021-07-13 | 2025-07-15 | 迈威(美国)生物治疗有限公司 | 抗c1s抗体和其用途 |
| CN114874329A (zh) * | 2022-05-19 | 2022-08-09 | 江苏大学 | 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用 |
| MA71249A (fr) | 2022-06-24 | 2025-04-30 | Bioverativ Usa Inc. | Méthodes de traitement de maladies médiées par complément |
| TW202426490A (zh) | 2022-11-21 | 2024-07-01 | 美商黛安瑟斯醫療運營公司 | 結合ｃ１ｓ之抗體及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| ES2912396T3 (es) * | 2012-11-02 | 2022-05-25 | Bioverativ Usa Inc | Anticuerpos anti-C1s del complemento y uso de los mismos |
| WO2015084999A1 (en) * | 2013-12-06 | 2015-06-11 | True North Therapeutics, Inc. | Complement component biomarker assays |
-
2018
- 2018-03-14 SG SG11201907583TA patent/SG11201907583TA/en unknown
- 2018-03-14 KR KR1020197029545A patent/KR102934707B1/ko active Active
- 2018-03-14 BR BR112019018950-5A patent/BR112019018950A2/pt unknown
- 2018-03-14 CA CA3055781A patent/CA3055781A1/en active Pending
- 2018-03-14 KR KR1020267006425A patent/KR20260039796A/ko active Pending
- 2018-03-14 TW TW107108658A patent/TWI848905B/zh active
- 2018-03-14 EP EP18715381.2A patent/EP3596121A1/en active Pending
- 2018-03-14 AU AU2018236267A patent/AU2018236267B2/en active Active
- 2018-03-14 MX MX2019010994A patent/MX2019010994A/es unknown
- 2018-03-14 US US16/494,267 patent/US20210115116A1/en not_active Abandoned
- 2018-03-14 WO PCT/US2018/022462 patent/WO2018170145A1/en not_active Ceased
- 2018-03-14 TW TW113122096A patent/TW202513092A/zh unknown
- 2018-03-14 IL IL269174A patent/IL269174B2/en unknown
- 2018-03-14 CN CN201880029619.1A patent/CN110753701A/zh active Pending
- 2018-03-14 JP JP2019550688A patent/JP7293122B2/ja active Active
- 2018-03-14 CR CR20190468A patent/CR20190468A/es unknown
- 2018-03-14 IL IL325084A patent/IL325084A/en unknown
-
2019
- 2019-09-13 MX MX2025010483A patent/MX2025010483A/es unknown
-
2023
- 2023-03-01 JP JP2023030606A patent/JP2023071824A/ja active Pending
-
2025
- 2025-01-31 JP JP2025014511A patent/JP2025072437A/ja active Pending
- 2025-06-12 AU AU2025204392A patent/AU2025204392A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2025204392A1 (en) | 2025-07-03 |
| TW202513092A (zh) | 2025-04-01 |
| TWI848905B (zh) | 2024-07-21 |
| CN110753701A (zh) | 2020-02-04 |
| AU2018236267B2 (en) | 2025-03-13 |
| BR112019018950A2 (pt) | 2020-04-22 |
| JP2020511469A (ja) | 2020-04-16 |
| SG11201907583TA (en) | 2019-09-27 |
| TW201842931A (zh) | 2018-12-16 |
| US20210115116A1 (en) | 2021-04-22 |
| IL269174B1 (en) | 2026-01-01 |
| EP3596121A1 (en) | 2020-01-22 |
| IL269174A (en) | 2019-11-28 |
| WO2018170145A1 (en) | 2018-09-20 |
| MX2025010483A (es) | 2025-10-01 |
| JP2025072437A (ja) | 2025-05-09 |
| KR20260039796A (ko) | 2026-03-20 |
| KR102934707B1 (ko) | 2026-03-06 |
| JP7293122B2 (ja) | 2023-06-19 |
| KR20190128676A (ko) | 2019-11-18 |
| IL269174B2 (en) | 2026-05-01 |
| JP2023071824A (ja) | 2023-05-23 |
| CR20190468A (es) | 2019-12-17 |
| IL325084A (en) | 2026-02-01 |
| AU2018236267A1 (en) | 2019-09-26 |
| CA3055781A1 (en) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20190468A (es) | Métodos para tratar enfermedades y trastornos mediados por completo | |
| MX2020001732A (es) | Tratamiento de las afecciones del sistema nervioso central. | |
| CL2023002682A1 (es) | Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos | |
| CO2022004902A2 (es) | Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| MX2019006177A (es) | Metodos para tratar afecciones inflamatorias. | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| MX2020009602A (es) | Formulaciones de pulverizacion de epinefrina. | |
| MX2020004005A (es) | Terapias genicas para los trastornos lisosomales. | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| MX2017009694A (es) | Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l). | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| MX2019003703A (es) | Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23. | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| MX2018010852A (es) | Metodos para tratar la depresion con antagonistas del receptor de orexina-2. | |
| CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
| MX376077B (es) | Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2. | |
| CL2017002526A1 (es) | Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares (divisional de solicitud n°2485-2015) | |
| MX2021003110A (es) | Agonistas del receptor x farnesoide y usos de los mismos. | |
| CL2021001389A1 (es) | Formulaciones en cápsula | |
| EA201790352A1 (ru) | Терапевтическое лечение на основе анаморелина | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| CL2019000625A1 (es) | Combinación de agonistas de fxr. | |
| MX2020003682A (es) | Metodos para tratar enfermedades asociadas con ciliopatias. | |
| UY35890A (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington |